AMARIN CORP PLC\UK Form 8-K April 18, 2011

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

## FORM 8-K

## **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): April 18, 2011

## **Amarin Corporation plc**

(Exact name of registrant as specified in its charter)

**England and Wales** (State or other jurisdiction

0-21392 (Commission Not applicable (I.R.S. Employer

of incorporation)

File Number)

**Identification No.)** 

First Floor, Block 3, The Oval, Shelbourne Road, Ballsbridge,


#### Dublin 4, Ireland (Address of principal executive offices) Registrant s telephone number, including area code: +353 1 6699 020

#### Not Applicable

Not applicable

(Zip Code)

Former name or former address, if changed since last report



- Without communications pursuant to Rule 125 under the Securities Feet (17 G1R 250.125)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Item 8.01. Other Events.

On April 18, 2011, Amarin Corporation plc (the Company) issued a press release announcing the top line results of its ANCHOR study, a Phase 3 clinical trial of its lead drug candidate AMR101. The full text this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

#### Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Press Release, dated April 18, 2011

\* \* \*

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 18, 2011 Amarin Corporation plc

By: /s/ John Thero John Thero President

#### **Exhibit Index**

Exhibit No.

Description Press Release, dated April 18, 2011 99.1